We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHMA
201
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.91M 0.06%
610,299
-120,000
-16% -$460K
KRRO icon
202
CALL
Korro Bio
KRRO
$150M
$1.9M 0.06%
+4,000
New +$7.77M
CRBP icon
203
Corbus Pharmaceuticals
CRBP
$166M
$1.9M 0.06%
32,137
+27,500
+593% +$1.81M
CLOV icon
204
CALL
Clover Health Investments
CLOV
$2.2B
$1.89M 0.06%
250,000
+100,000
+67% +$1.13M
BLCM
205
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$1.88M 0.06%
500,000
– –
INCY icon
206
Incyte
INCY
$24.2B
$1.87M 0.06%
+23,012
New +$1.96M
AGEN
207
Agenus
AGEN
$312M
$1.85M 0.06%
34,587
-13,815
-29% -$998K
CRSP icon
208
CRISPR Therapeutics
CRSP
$4.73B
$1.84M 0.06%
+15,084
New +$2.28M
ORTX
209
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$1.81M 0.06%
+25,000
New +$1.78M
ACET icon
210
Adicet Bio
ACET
$85.2M
$1.77M 0.06%
8,443
-2,449
-22% -$562K
MBIO icon
211
Mustang Bio
MBIO
$4.32M
$1.75M 0.06%
701
– –
PDSB icon
212
PDS Biotechnology
PDSB
$38.4M
$1.75M 0.06%
+383,373
New +$1.54M
CVM icon
213
CALL
CEL-SCI Corp
CVM
$20.3M
$1.63M 0.05%
+3,563
New +$1.95M
TPST icon
214
Tempest Therapeutics
TPST
$13.7M
$1.62M 0.05%
6,913
+6,220
+898% +$2.51M
CYTO
215
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.6M 0.05%
+1,154
New +$1.55M
NTBL
216
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$1.6M 0.05%
+22,880
New +$1.79M
BIIB icon
217
Biogen
BIIB
$30B
$1.59M 0.05%
5,700
– –
BLU
218
DELISTED
BELLUS Health Inc.
BLU
$1.54M 0.05%
400,000
+300,000
+300% +$1.14M
CLNN icon
219
Clene
CLNN
$64M
$1.52M 0.05%
+5,927
New +$1.3M
HYFT
220
MindWalk Holdings
HYFT
$60.6M
$1.47M 0.05%
+150,000
New +$2.05M
CMRX
221
CALL
DELISTED
Chimerix, Inc.
CMRX
$1.45M 0.05%
+150,000
New +$1.38M
VIRX
222
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.44M 0.05%
155,599
+98,456
+172% +$1.03M
SRRK icon
223
CALL
Scholar Rock
SRRK
$5.67B
$1.43M 0.05%
+28,300
New +$1.57M
WVE icon
224
CALL
Wave Life Sciences
WVE
$1.09B
$1.4M 0.05%
+250,000
New +$2.4M
SRNE
225
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$1.37M 0.05%
+165,900
New +$1.75M
7 8
9
10 11

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.